Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.42 |
| ▸ | HTR1A | P08908 | 8/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7404020 | 0.98 | GBA1 (0.52) | GBA1SLC6A4SLC6A2HTR1ASLC6A3 | |
| SCHEMBL14469029 | 0.89 | HRH4 (0.42) | GBA1SLC6A4SLC6A2HTR1ASLC6A3 | |
| SCHEMBL23119304 | 0.88 | GBA1 (0.46) | GBA1SLC6A4SLC6A2HTR1ASLC6A3 | |
| SCHEMBL23119227 | 0.84 | SLC6A2 (0.49) | GBA1SLC6A4SLC6A2HTR1ASLC6A3 | |
| SCHEMBL3964709 | 0.80 | GBA1 (0.49) | GBA1SLC6A4SLC6A2HTR1ASLC6A3 | |
| SCHEMBL21005952 | 0.80 | SLC6A2 (0.42) | SLC6A4SLC6A2HTR1ASLC6A3GRIN1 | |
| SCHEMBL3965587 | 0.79 | GBA1 (0.56) | GBA1SLC6A4SLC6A2HTR1ASLC6A3 | |
| SCHEMBL7494499 | 0.79 | SLC6A4 (0.48) | GBA1SLC6A4SLC6A2HTR1ASLC6A3 | |
| Hydrochloric Acid SCHEMBL4574857 | 0.78 | GBA1 (0.55) | GBA1SLC6A4SLC6A2HTR1ASLC6A3 | |
| Hydrochloric Acid SCHEMBL7984004 | 0.78 | SLC6A4 (0.47) | GBA1SLC6A4SLC6A2HTR1ASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220202963-A1 | RADIOLABELED COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-06-30 | — | — | US | disclosed |
| WO-2021048241-A1 | RADIOLABELED COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-03-18 | — | — | WO | disclosed |
| EP-1565453-A4 | 2- (4-BENZYL)-1-PIPERIDINYL)METHYL|BENZIMIDAZOLE-5-OL DERIVATIVES AS NR2B RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20060160853-A1 | 2-[(4-Benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists | MERCK & CO., INC. | 2006-07-20 | — | — | US | disclosed |
| EP-1565453-A1 | 2- (4-BENZYL)-1-PIPERIDINYL)METHYL]BENZIMIDAZOLE-5-OL DERIVATIVES AS NR2B RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2005-08-24 | — | — | EP | disclosed |
| EP-1089735-B1 | 4-BENZYL PIPERIDINE ALKYLSULFOXIDE HETEROCYCLES AND THEIR USE AS SUBTYPE-SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004048364-A1 | 2-[(4-BENZYL)-1-PIPERIDINYL)METHYL]BENZIMIDAZOLE-5-OL DERIVATIVES AS NR2B RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2004-06-10 | — | — | WO | disclosed |
| EP-1089735-A4 | 4-BENZYL PIPERIDINE ALKYLSULFOXIDE HETEROCYCLES AND THEIR USE AS SUBTYPE-SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6284774-B1 | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | WARNER-LAMBERT COMPANY | 2001-09-04 | — | — | US | disclosed |
| EP-1089735-A1 | 4-BENZYL PIPERIDINE ALKYLSULFOXIDE HETEROCYCLES AND THEIR USE AS SUBTYPE-SELECTIVE NMDA RECEPTOR ANTAGONISTS | Warner-Lambert Company LLC (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000000197-A1 | 4-BENZYL PIPERIDINE ALKYLSULFOXIDE HETEROCYCLES AND THEIR USE AS SUBTYPE-SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2000-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160853-A1 | 2-[(4-Benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists | GRIN2B, GRIN1, GRIN2A | GBA1 2386/4885SLC6A4 779/4885SLC6A2 2518/4885 |
| US-20220202963-A1 | RADIOLABELED COMPOUNDS | MGLL, PNLIP, LPL | GBA1 63/4885SLC6A4 2415/4885SLC6A2 1911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.